$NTRA
Natera, Inc.

2020 Q2 Form 10-Q Financial Statement

#000155837020005858 Filed on May 08, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $86.47M $94.01M $66.82M
YoY Change 16.3% 40.69% 7.19%
Cost Of Revenue $42.73M $41.52M $41.61M
YoY Change 3.26% -0.2% 2.48%
Gross Profit $43.74M $52.49M $23.52M
YoY Change 43.27% 123.17% 8.15%
Gross Profit Margin 50.58% 55.84% 35.2%
Selling, General & Admin $68.19M $65.68M $43.83M
YoY Change 44.95% 49.85% 15.65%
% of Gross Profit 155.89% 125.13% 186.35%
Research & Development $23.01M $18.23M $11.44M
YoY Change 89.75% 59.38% -20.03%
% of Gross Profit 52.59% 34.72% 48.62%
Depreciation & Amortization $2.210M $1.826M $1.920M
YoY Change -44.08% -4.9% 3.23%
% of Gross Profit 5.05% 3.48% 8.16%
Operating Expenses $91.19M $83.91M $55.27M
YoY Change 54.13% 51.82% 5.67%
Operating Profit -$51.66M -$34.87M -$31.75M
YoY Change 80.4% 9.85% 3.91%
Interest Expense $4.038M $2.464M $2.724M
YoY Change 48.4% -9.54% -213.5%
% of Operating Profit
Other Income/Expense, Net $1.900M $2.000M $500.0K
YoY Change 137.5% 300.0% 400.0%
Pretax Income -$59.62M -$35.35M -$34.02M
YoY Change 95.35% 3.92% 3.71%
Income Tax $15.00K $23.00K $74.00K
% Of Pretax Income
Net Earnings -$59.64M -$35.37M -$34.09M
YoY Change 83.97% 3.76% 3.71%
Net Earnings / Revenue -68.97% -37.62% -51.02%
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$753.5K -$452.1K -$0.54
COMMON SHARES
Basic Shares Outstanding 78.73M 78.25M 62.83M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $571.2M $405.8M $128.1M
YoY Change 140.0% 216.78% 12.66%
Cash & Equivalents $77.32M $74.10M $34.68M
Short-Term Investments $493.9M $331.7M $93.80M
Other Short-Term Assets $15.60M $15.70M $6.000M
YoY Change 168.97% 161.67% -48.28%
Inventory $18.03M $14.16M $13.70M
Prepaid Expenses
Receivables $58.71M $61.58M $60.30M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $663.5M $497.2M $208.1M
YoY Change 106.06% 138.93% 10.99%
LONG-TERM ASSETS
Property, Plant & Equipment $25.93M $26.72M $50.60M
YoY Change -46.33% -47.2% 88.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.36M $12.09M $2.800M
YoY Change -5.67% 331.89% -34.88%
Total Long-Term Assets $59.76M $61.43M $53.30M
YoY Change -2.52% 15.26% 70.83%
TOTAL ASSETS
Total Short-Term Assets $663.5M $497.2M $208.1M
Total Long-Term Assets $59.76M $61.43M $53.30M
Total Assets $723.3M $558.6M $261.4M
YoY Change 88.69% 113.71% 19.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.450M $8.369M $8.900M
YoY Change -58.43% -5.97% 3.49%
Accrued Expenses $53.08M $50.39M $37.60M
YoY Change 38.23% 34.02% 9.3%
Deferred Revenue $52.39M $51.84M
YoY Change
Short-Term Debt $50.10M $50.10M $50.20M
YoY Change 0.0% -0.2%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $175.6M $176.6M $112.7M
YoY Change 38.35% 56.74% 7.95%
LONG-TERM LIABILITIES
Long-Term Debt $197.5M $72.90M $73.40M
YoY Change 168.71% -0.68% 0.41%
Other Long-Term Liabilities $310.0K $310.0K $70.40M
YoY Change -99.65% -99.56% 56.44%
Total Long-Term Liabilities $310.0K $310.0K $143.8M
YoY Change -99.81% -99.78% 21.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $175.6M $176.6M $112.7M
Total Long-Term Liabilities $310.0K $310.0K $143.8M
Total Liabilities $419.0M $299.7M $256.5M
YoY Change 44.38% 16.85% 15.28%
SHAREHOLDERS EQUITY
Retained Earnings -$794.6M -$734.9M -$699.2M
YoY Change 5.11%
Common Stock $1.093B $988.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $304.3M $258.9M $4.986M
YoY Change
Total Liabilities & Shareholders Equity $723.3M $558.6M $261.4M
YoY Change 88.69% 113.71% 19.52%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$59.64M -$35.37M -$34.09M
YoY Change 83.97% 3.76% 3.71%
Depreciation, Depletion And Amortization $2.210M $1.826M $1.920M
YoY Change -44.08% -4.9% 3.23%
Cash From Operating Activities -$40.98M -$35.10M -$31.82M
YoY Change 14.63% 10.31% -3130.38%
INVESTING ACTIVITIES
Capital Expenditures -$2.210M $7.917M $955.0K
YoY Change -238.21% 729.01% -212.35%
Acquisitions
YoY Change
Other Investing Activities -$163.2M $51.41M $13.87M
YoY Change 44.11% 270.66% -46.47%
Cash From Investing Activities -$165.4M $43.49M $12.92M
YoY Change 63.81% 236.7% -48.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 209.6M 3.826M 2.578M
YoY Change 81.12% 48.41% 352.28%
NET CHANGE
Cash From Operating Activities -40.98M -35.10M -31.82M
Cash From Investing Activities -165.4M 43.49M 12.92M
Cash From Financing Activities 209.6M 3.826M 2.578M
Net Change In Cash 3.180M 12.22M -16.32M
YoY Change -115.13% -174.85% -161.18%
FREE CASH FLOW
Cash From Operating Activities -$40.98M -$35.10M -$31.82M
Capital Expenditures -$2.210M $7.917M $955.0K
Free Cash Flow -$38.77M -$43.02M -$32.77M
YoY Change 3.8% 31.25% -1824.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78652000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78005000
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
CY2019Q1 ntra Number Of Investments Sold
NumberOfInvestmentsSold
0
CY2020Q1 ntra Number Of Investments Sold
NumberOfInvestmentsSold
0
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604821
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Entity Address Country
EntityAddressCountry
US
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity File Number
EntityFileNumber
001-37478
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Industrial Road, Suite 410
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
CY2020Q1 dei City Area Code
CityAreaCode
650
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
249-9090
CY2020Q1 dei Security12g Title
Security12gTitle
Common Stock, par value $0.0001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
NTRA
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78725320
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74144000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61926000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
55000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
55000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
331681000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
379065000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3020000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2919000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
61577000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
53351000
CY2020Q1 us-gaap Inventory Net
InventoryNet
14161000
CY2019Q4 us-gaap Inventory Net
InventoryNet
12394000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15590000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16376000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
497208000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
523167000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26718000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23283000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22620000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23730000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12093000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12476000
CY2020Q1 us-gaap Assets
Assets
558639000
CY2019Q4 us-gaap Assets
Assets
582656000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8369000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8604000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15953000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16088000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50393000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49043000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51840000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56016000
CY2020Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
50087000
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
50123000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
176642000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
179874000
CY2020Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
72881000
CY2019Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
73656000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
25152000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23808000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24727000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26297000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
310000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
310000
CY2020Q1 us-gaap Liabilities
Liabilities
299712000
CY2019Q4 us-gaap Liabilities
Liabilities
303945000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78652000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78005000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
988199000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
976955000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-734946000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-699171000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5666000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
919000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
258927000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
278711000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
558639000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
582656000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66824000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41520000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41605000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18225000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11435000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
65681000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43832000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
128884000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
98570000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34872000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-31746000
CY2020Q1 us-gaap Interest Expense
InterestExpense
2464000
CY2019Q1 us-gaap Interest Expense
InterestExpense
2724000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1987000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
453000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35349000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34017000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
258927000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-35372000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-34091000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1826000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1920000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
-64000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1703000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
216000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3227000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2135000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-99000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
101000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35372000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35372000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-34091000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4747000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
286000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30625000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33805000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78287000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62831000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32162000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2578000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4051000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
286000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-34091000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
4986000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
278711000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3826000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7418000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4747000
CY2020Q1 ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-403000
CY2020Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
721000
CY2019Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
70000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7417000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4051000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1940000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1890000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121000
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
98000
CY2020Q1 us-gaap Payments For Other Operating Activities
PaymentsForOtherOperatingActivities
57000
CY2019Q1 us-gaap Proceeds From Other Operating Activities
ProceedsFromOtherOperatingActivities
8000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1387000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8786000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2145000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
217000
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1850000
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-201000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-135000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5466000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
28191000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2657000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-734900000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-699200000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74100000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
331700000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
331700000
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3348000
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1018000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2832000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
437000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35100000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31819000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
53876000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
18628000
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
11500000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
93785000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
32500000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7917000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
955000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43492000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12917000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3826000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2578000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3826000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2578000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12218000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16324000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61981000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51004000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74199000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34680000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35400000
CY2019Q1 ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-400000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2020Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
50100000
CY2019Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108100000
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2019Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
216200000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;text-indent:40.3pt;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, the operating right-of-use assets and the associated lease liabilities, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of common stock, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements. </p>
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3300000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1400000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
400000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
4300000
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the response to the pandemic information is rapidly evolving. Our test volumes began to decrease in the second half of March 2020 as a result of the COVID-19 pandemic spreading to the United States and resulting limitations and reordering of priorities across the U.S. healthcare system. The Company expects test volumes to continue to be adversely affected by COVID-19 and cannot predict when volumes will return to normal. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of financial conditions for insurance carriers, patients, clinics and laboratory partners and generally does not require collateral to support credit sales. For the three months ended March 31, 2020, and 2019, there were no customers exceeding 10% of total revenues on an individual basis. As of March 31, 2020 and December 31, 2019, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p>
CY2020Q1 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
1100000
CY2019Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
1200000
CY2020Q1 ntra Increase Decrease Accumulated Other Comprehensive Income Loss
IncreaseDecreaseAccumulatedOtherComprehensiveIncomeLoss
4747000
CY2019Q1 ntra Increase Decrease Accumulated Other Comprehensive Income Loss
IncreaseDecreaseAccumulatedOtherComprehensiveIncomeLoss
286000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66824000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66824000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66824000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
127898000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
61577000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
53351000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51840000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56016000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
25152000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23808000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
76992000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
79824000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
79824000
CY2020Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
710000
CY2020Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-3455000
CY2020Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-87000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
76992000
CY2020Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-3500000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
10
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
128675000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
198137000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
203006000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
326035000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
331681000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70069000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64807000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43351000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41524000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26718000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23283000
CY2020Q1 us-gaap Depreciation
Depreciation
1800000
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1912000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1850000
CY2020Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
6997000
CY2019Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
5767000
CY2020Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2017000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5710000
CY2020Q1 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
5027000
CY2019Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
2761000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15953000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16088000
CY2020Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
11599000
CY2019Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
8408000
CY2020Q1 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
7821000
CY2019Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
9410000
CY2020Q1 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
6051000
CY2019Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
4301000
CY2020Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2136000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2957000
CY2020Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
5055000
CY2019Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2873000
CY2020Q1 ntra Accrued Shipping Charges
AccruedShippingCharges
209000
CY2019Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
305000
CY2020Q1 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1412000
CY2019Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1691000
CY2020Q1 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
1066000
CY2019Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
2269000
CY2020Q1 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
1157000
CY2019Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
1092000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5947000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5739000
CY2020Q1 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
643000
CY2019Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1482000
CY2020Q1 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
7297000
CY2019Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
8516000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50393000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49043000
CY2019Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
9410000
CY2018Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
10012000
CY2020Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
4684000
CY2019Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
2504000
CY2020Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
2495000
CY2019Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
1465000
CY2020Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
11599000
CY2019Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
11051000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1027000
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
478000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5947000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24727000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
30674000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M17D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1077
CY2020Q1 us-gaap Lease Cost
LeaseCost
1900000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2100000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6633000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9067000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9319000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7797000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2400000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4730000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39946000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9272000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
30674000
CY2016 ntra Shareholders Percent Of Total
ShareholdersPercentOfTotal
0.05
CY2020Q1 us-gaap Purchase Obligation
PurchaseObligation
37223000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
4140000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
88000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2020Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2119000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1344000
CY2019Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
25000
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
CY2020Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
72881000
CY2019Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
73656000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1300000
CY2020Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2100000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000
CY2020Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9000000.0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8600000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2020Q1 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-35372000
CY2019Q1 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-34091000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78287000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62831000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12722000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11718000

Files In Submission

Name View Source Status
0001558370-20-005858-index-headers.html Edgar Link pending
0001558370-20-005858-index.html Edgar Link pending
0001558370-20-005858.txt Edgar Link pending
0001558370-20-005858-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20200331xex31d1.htm Edgar Link pending
ntra-20200331xex31d2.htm Edgar Link pending
ntra-20200331xex32d1.htm Edgar Link pending
ntra-20200331xex32d2.htm Edgar Link pending
ntra-20200507.xsd Edgar Link pending
ntra-20200507x10q.htm Edgar Link pending
ntra-20200507x10q_htm.xml Edgar Link completed
ntra-20200507_cal.xml Edgar Link unprocessable
ntra-20200507_def.xml Edgar Link unprocessable
ntra-20200507_lab.xml Edgar Link unprocessable
ntra-20200507_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending